D-NMAPPD
Based on 1 publication(s) in Google Scholar
D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.74%
- No. CAS: 35922-06-6
- Fòrmula: C23H38N2O5
- Peso molecular:422.56
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Lipid Metabolism Compound Library
HY-L091
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) D-NMAPPD
MoreVer todos los productos específicos de isoformas iGluR
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
1.5 μM
Compound: B-13
|
Cytotoxicity against human HL60 cells assessed as growth inhibition by trypan blue dye exclusion assay
Cytotoxicity against human HL60 cells assessed as growth inhibition by trypan blue dye exclusion assay
|
[PMID: 23312611] |
| MCF7 | IC50 |
14 μM
Compound: B13
|
Antiproliferative activity against human MCF7 cells after 48 hrs
Antiproliferative activity against human MCF7 cells after 48 hrs
|
[PMID: 17869115] |
| MCF7 | IC50 |
19.6 μM
Compound: B13
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 19217788] |
| MCF7 | IC50 |
27.7 μM
Compound: B13
|
Inhibition of ACDase in human MCF7 cell lysate using [9,10-3H] De-C16-Cer substrate after 1 hr by scintillation counting analysis
Inhibition of ACDase in human MCF7 cell lysate using [9,10-3H] De-C16-Cer substrate after 1 hr by scintillation counting analysis
|
[PMID: 25456083] |
| MCF7 | IC50 |
35.59 μM
Compound: (1R,2R)-B13; D-NMAPPD
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 33461145] |
| MCF7 | IC50 |
37.01 μM
Compound: (1R,2R)-B13; D-NMAPPD
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 33461145] |
| MCF7 | IC50 |
42.27 μM
Compound: (1R,2R)-B13; D-NMAPPD
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 33461145] |
| Sf9 | IC50 |
120 μM
Compound: B-13
|
Inhibition of recombinant human nCDase expressed in Sf9 cells using fluorescently-labeled acyl-NBD-C12-ceramide as substrate after 2 hrs by fluorescence assay
Inhibition of recombinant human nCDase expressed in Sf9 cells using fluorescently-labeled acyl-NBD-C12-ceramide as substrate after 2 hrs by fluorescence assay
|
[PMID: 22989912] |
In rat hippocampal slices, D-NMAPPD exhibit increased N-methyl-D-aspartate (NMDA) receptor-mediated field excitatory postsynaptic potentials (fEPSPs) in CA1 synapses[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 35922-06-6
-
Appearance Solid
-
Peso molecular 422.56
-
Fòrmula C23H38N2O5
-
Color White to off-white
-
SMILES
OC[C@H]([C@@H](C1=CC=C(C=C1)[N+]([O-])=O)O)NC(CCCCCCCCCCCCC)=O
-
Synonyms
(1R,2R)-B13
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Pathog Dis
2024 Jul 19:ftae016. PMID: 39030066
Solvente y solubilidad
DMSO : 200 mg/mL (473.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Marie-Elaine Laurier-Laurin, et al.Blockade of lysosomal acid ceramidase induces GluN2B-dependent Tau phosphorylation in rat hippocampal slices. Neural Plast. 2014;2014:196812. [Content Brief]
[2]. M Selzner, et al.Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001 Feb 1;61(3):1233-40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3665 mL | 11.8326 mL | 23.6653 mL | 59.1632 mL |
| 5 mM | 0.4733 mL | 2.3665 mL | 4.7331 mL | 11.8326 mL | |
| 10 mM | 0.2367 mL | 1.1833 mL | 2.3665 mL | 5.9163 mL | |
| 15 mM | 0.1578 mL | 0.7888 mL | 1.5777 mL | 3.9442 mL | |
| 20 mM | 0.1183 mL | 0.5916 mL | 1.1833 mL | 2.9582 mL | |
| 25 mM | 0.0947 mL | 0.4733 mL | 0.9466 mL | 2.3665 mL | |
| 30 mM | 0.0789 mL | 0.3944 mL | 0.7888 mL | 1.9721 mL | |
| 40 mM | 0.0592 mL | 0.2958 mL | 0.5916 mL | 1.4791 mL | |
| 50 mM | 0.0473 mL | 0.2367 mL | 0.4733 mL | 1.1833 mL | |
| 60 mM | 0.0394 mL | 0.1972 mL | 0.3944 mL | 0.9861 mL | |
| 80 mM | 0.0296 mL | 0.1479 mL | 0.2958 mL | 0.7395 mL | |
| 100 mM | 0.0237 mL | 0.1183 mL | 0.2367 mL | 0.5916 mL |
D-NMAPPD Related Classifications
HY-124962 Related Classifications
Powered by Bioz